FIELD: medicine.
SUBSTANCE: invention relates to a method for preventing or treating proliferative disorder in a mammal. Method comprises administering to a mammal a platinum-containing medicinal agent, an immune control point inhibitor, containing an anti-CTLA-4 antibody, an anti-PD1 antibody or an anti-PD-L1 antibody, and a peptide compound containing (d-Bpa)(d-Ser)(d-Trp)(d-Ser)(d-Phe-2,3,4,5,6-F)(d-Cha) (SEQ ID NO: 1).
EFFECT: said combined treatment showed significant tumor growth reduction compared to a mammal, treated with said platinum-containing drug, or an immune control point inhibitor, or a combination thereof; combination of a platinum-containing drug and a peptide compound (SEQ ID NO: 1) enhances the antitumor activity of the immune control point inhibitor.
43 cl, 32 dwg, 15 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDES AND PEPTIDOMIMETICS FOR COMBINED USE AND TREATMENT IN A SUBPOPULATION OF PATIENTS WITH CANCER DISEASES | 2014 |
|
RU2732440C2 |
| PEPTIDE ANALOG OF ACYLATED OXYNTOMODULIN | 2018 |
|
RU2752787C1 |
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
| LONG-ACTING DOUBLE AGONIST OF GLUCAGON-LIKE PEPTIDE-1 AND GLUCAGON RECEPTORS | 2021 |
|
RU2799327C1 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| IMPROVED PEPTIDE DRUGS FOR TREATMENT OF NASH AND OTHER DISORDERS | 2019 |
|
RU2790209C2 |
| ANTIBODY SPECIFICALLY BINDING TO ICAM-1 AND ITS USE | 2019 |
|
RU2789757C2 |
| PEPTIDE HAVING ACTIVITY OF HUMAN SLURP-1 PROTEIN AND ITS APPLICATION FOR SUPPRESSION OF GROWTH OF CARCINOMA AND GLIOMA, PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF GROWTH OF CARCINOMA AND GLIOMA, AND METHOD FOR SUPPRESSION OF GROWTH OF CARCINOMA AND GLIOMA USING THE SPECIFIED PEPTIDE | 2022 |
|
RU2792364C1 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
